News

News 2017-08-28T19:48:57+00:00

May 2017

Studies Further Validate Safety, Efficacy and an Improved Patient Experience in Use of the C2 Cryoballoon® Ablation System for Primary Treatment of Barrett’s Esophagus

REDWOOD CITY, Calif. – May 9, 2017 – C2 Therapeutics marked Digestive Disease Week by releasing the results of clinical studies that help further validate the utility of the C2 CryoBalloon®  Ablation System (CbAS) for ablation of Barrett’s esophagus.

C2 CryoBalloon Focal Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s esophagus with dysplasia.

Click here to see full release.

January 2017

PENTAX Medical Expands Interventional Endoscopy Offering with Acquisition of C2 Therapeutics

Press Release (U.S.A. version) – Outside U. S. A. version follows after U. S. A. version

Montvale, NJ – January 9, 2017 – PENTAX Medical, a division of the HOYA Group, Tokyo, Japan announced today that they have acquired C2 Therapeutics, Redwood City, CA for an undisclosed amount. C2 Therapeutics develops the C2 CryoBalloon™ Ablation System for the endoscopic ablation of unwanted tissue such as Barrett’s esophagus1. This acquisition will help strengthen the company’s therapeutic endoscopy portfolio.

Click here to see full release.

June 2016

C2 Therapeutics Announces Initiation of Coldplay III Trial Validating The C2 CryoBalloon™ Focal Ablation System for Primary Treatment of Barrett’s Esophagus

REDWOOD CITY, Calif. – June 7, 2016 – C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system in patients with Barrett’s esophagus.

Click here to see full release.

May 2016

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System

REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 – 24 in San Diego.

Click here to see full release.

January 2016

C2 Therapeutics Announces Leadership Team Expansion

REDWOOD CITY, Calif. – January 26, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced the appointment of five new members to its leadership team. These individuals join an existing team of seasoned leaders who will be instrumental in enabling C2 Therapeutics’ continued development and growth.

Click here to see full release.

October 2015

CE Mark Granted for Novel Cryoablation Device Aimed at Reducing the Incidence of Esophageal Cancer

Redwood City, Calif. – October 22, 2015 – C2 Therapeutics, a privately-held company founded to improve treatment of precursors to esophageal cancer (Barrett’s Esophagus or BE), today announced that it received the CE (Conformité Européenne) mark for its Coldplay CryoBalloon® Focal Ablation System. The product is now available for commercial use initially in parts of Western Europe. Cryoablation is a process that uses extreme cold to precisely destroy or damage diseased tissue while minimizing damage to surrounding healthy tissue.

Click here to see full release.

MKTG 1071 REV A